The subject disclosure relates to nerve monitoring systems, and particularly to remote control of nerve monitoring systems.
This section provides background information related to the present disclosure which is not necessarily prior art.
Nerve monitoring systems such as the NIM-Response® 3.0 and/or NIM-Neuro® 3.0 nerve monitoring systems, sold by Medtronic, Inc., may be used to monitor electromyography (EMG) responses. In particular, the monitoring systems may provide stimulation at a selected nerve and a response sensed or detected at muscles remote from the location of the stimulation. Monitoring the EMG responses may be used to determine whether one or more nerves has been damaged during a select procedure. In various systems, the monitoring system may be controlled by a monitor user that is spaced apart from a procedure user and a subject. Therefore, the monitor user may require instructions from the procedure user to operate the monitoring system according to a selected use by the procedure user.
This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.
A nerve monitoring system may be used to monitor the integrity of a nerve. During a procedure, a procedure user may operate and/or alter an operation of the nerve monitoring system with a remote control system provided at the procedure user. The remote control system may include hardware that can be manipulated by the procedure user at the procedure user's location. Therefore, instructions or control to the nerve monitoring system may be provided at a location remote from the monitoring system.
The monitoring system may include a processor and display system for displaying results from the nerve monitoring. The monitoring system, however, may not be immediately available for placement in a sterile field or for placement proximal to a subject. The subject may be monitored with the monitoring system for a selected procedure. The procedure user may include a surgeon. The surgeon may be sterile for the selected procedure. A remote control may be connected to a monitoring and/or stimulating instrument during a procedure. A remote control may also be connected to the surgeon and interconnected with the instrument and the monitoring system. The remote control may be sterile and appropriate for placement in the sterile field.
The remote control includes a physical connection to the monitoring system with a length of conductive material. The physical connection may include a wire (e.g. copper or aluminum wire), conductive polymer, or other appropriate conductive material. The physical connection may allow for both a signal from the remote to the monitoring system to interact with the monitoring system and/or to transmit a signal to and/or from the instrument.
Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.
Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.
Example embodiments will now be described more fully with reference to the accompanying drawings.
With initial reference to
The monitor assembly 20 may further include a processor 26 and a memory 28. It is understood that the processor 26 may access the memory 28 to execute instructions stored thereon or access other data on the memory 28. The memory 28 may include a physical memory, such as a spinning hard disk drive, solid state memory, or other appropriate types of memory. Further, the memory 28 may not be incorporated into the monitor assembly 20, but may be accessed by processor 26, such as via communications network. The processor 26 may be a general purpose processor that is operable to execute instructions for generating a selected output, as discussed further herein. The processor 26 may further include onboard memory. Moreover, the processor 26 may include a specific purpose processor such as an application specific integrated circuit (ASIC). Accordingly, the processor 26 may execute instructions stored on memory 28, which may be a non-transitory memory, to provide an output for display on the display device 22.
The monitoring system 20 may further include a stimulation portion and/or generator. The stimulation portion may be configured to generate a voltage based upon control by the processor 26. The processor 26 may execute instructions of a program stored on the memory 28 and/or control by a user 30. As discussed herein, the monitoring system 20, therefore, may be operated to generate a stimulation at or with a stimulation instrument based upon control of the user 30.
The information displayed on the display device 22 may include information selected by the user 30. The selection made by the user 30 may be desired or selected information regarding a subject 34. The subject 34 is illustrated as a human subject, but it is understood that the subject may be any appropriate living subject, including non-human subjects. Further, the monitoring system 16 may be used with non-living subjects. Non-living subjects may have systems that are selected to be monitored for selected activity, such as electrical activity, and the monitoring system 16 may be used. In selected embodiments, however, the user 30 may be performing a surgical procedure on the subject 34. The user 30, therefore, may select to monitor nerve response and/or integrity such as by monitoring electromyography (EMG) responses.
One or more stimulation or monitoring assemblies may be incorporated in the monitoring system 16 and connected with the monitor assembly 20. For example, in various procedures such as a thyroidectomy or other thyroid surgeries, monitoring of a recurrent laryngeal nerve (RLN), a vagus nerve, or other appropriate nerve 36, in the subject 30. Other or alternative nerves may also be monitored, including other selected cranial nerves and/or spinal nerves. Monitoring of the RLN may include a nerve monitoring esophageal tube 38, which may have one or more conductive electrodes 40 that are in contact with selected portions of the subject 34. The electrode 40 may be affixed to an exterior of the tube 38 and/or incorporated into the structure of the tube 38. The electrode 40 can be connected to the monitor assembly 20 via a connection 42.
In addition, other instruments may be connected to the monitor assembly 20, such as electrode assemblies, including an electrode that may send or receive periodic stimulation pulses. In various embodiments, one or more stimulation instruments 50 may be used. The stimulation instrument 50 may be connected to the monitor assembly 20 with a connector 54. The connector 54 may allow for a physical connection between the stimulation instrument 50 and the monitoring assembly 20. The connector 54 may include a conductive member (e.g. a metal wire, conductive polymer, etc.). The stimulation instrument 50 may include various instruments such as surgical instruments and the like. Examples of stimulation instruments include those disclosed in U.S. patent application Ser. No. 14/678,485 filed on Apr. 3, 2015 and U.S. patent application Ser. No. 14/678,452 filed on Apr. 3, 2015; both incorporated herein by reference.
The stimulation instrument 50 is connected with the monitor assembly 20 with the connector 54 to send and/or receive stimulation signals to the subject 34 to assist in determining whether nerve damage or other tissue damage has occurred or could occur. A surgical instrument, such as a scalpel, may be manipulated by the user 30, such as a human surgeon. The surgical instrument may not or need not be directly connected to the monitor assembly 20. The stimulation instrument 50, however, may access various portions of the subject 34, such as through an incision 58. The stimulation instrument 50 may be used to contact the nerve 36 or tissue near the nerve 36 to stimulate a response in the nerve or an EMG response at a location located a distance from the location of the stimulus application.
The monitor assembly 20 may be provided to monitor signals through or from the stimulation instrument 50 without requiring interactive stimulation or monitoring through the scalpel while performing the procedure on the subject 34. It is understood, however, that other electrode assemblies may be connected to the subject 34 as is understood by one skilled in the art. Stimulation to the subject 34 may account for a refractory period of one or more nerves.
The operation of the monitoring system and the use of the monitoring system 16 may be similar to the NIM® monitoring system sold by Medtronic, Inc., including the NIM-Response® 3.0 nerve monitoring system. In operation, the stimulation instrument 50 may be placed on contact, or at least in stimulation connection, with the nerve 36, as discussed further herein, and a signal may be transmitted along the connection 54 from the monitor system 20. The electrode 40 on the tube 38 may be a receiving electrode. It is understood, however, that other receiving electrodes may be associated and/or in contact with the subject 34.
During a procedure, user 30 may attempt or select to determine whether the integrity or continuity of the nerve 36 has been damaged during the surgical procedure. For example, various cutting or tissue moving procedures may strain or cause damage to the nerve 36 and ensuring that the nerve 36 is undamaged may be selected. The user 30, therefore, may position the instrument 50 near and/or in contact with the nerve 36. The monitoring system 16, including the stimulation system or generator of the monitoring assembly 20, may provide a stimulating voltage and/or current through the instrument 50 to attempt to evoke a response in a tissue 70. The tissue 70 may include a muscle that upon an evoked response will cause movement of the muscle 70 and/or associated tissues, such as vocal folds. The evoked response may be sensed by the EMG sensing electrodes 40 and the signal may be transmitted to the monitoring assembly 20 to allow a presentation of a message to the user 30, such as a graph, warning, auditory message (e.g. tone representing a signal received regarding the evoked EMG), or the like. The user 30 may control the monitoring assembly 20 with a remote control 100.
The remote control 100 may be positioned with the user 30, according to various embodiments, such as being connected to the instrument 50. The remote control 100 may be removably connected to the instrument 50, as discussed further herein. The remote control 100 may include switches that allow operation or control of all or certain functions of the monitoring assembly 20 while using the monitoring system 16.
The monitoring system 16 may include certain portions such as the tube assembly 38 and the instrument 50 that are configured to be used in a sterile field area 104 which is separated from a non-sterile area 110. According to various embodiments, a physical structure may be positioned to separate the sterile field 104 from the non-sterile field 110 in an operating theatre or other selected location. Nevertheless, the monitoring assembly 20, including the various inputs, such as the keyboard 24c, may not generally be accessible to the user 30 if the user 30 is in the sterile field 104. The user 30 may attempt to provide instructions to a second user in the non-sterile field 110 to operate the monitoring assembly 20, which may be inefficient. Accordingly, the remote control 100 may allow the user 30 to directly control at least portions or certain operations of the monitoring assembly 20 without moving out of the sterile field 104.
Control of the monitoring assembly 20 by the user 30 from within the sterile field 104 may allow the user 30 to make immediate decisions and configuration selections regarding operation of the monitoring system 16. Moreover, the user 30 may be a distance from the other input devices, such as the keyboard 24c, and the remote 100 may be local (e.g. within arm's length or closer) to the user 30. As discussed above, the monitoring system 16 may be used to determine or confirm integrity of the nerve 36 by providing stimulation through the nerve 36 to evoke a response in the muscle 70. Therefore, the user 30 may wish to alter a configuration or operation of the monitoring system 16 during a use of the monitoring system 16 without attempting to convey the selected change of configuration as verbal or other types of instructions to a second user or individual to attempt to reconfigure or change operation of the monitoring assembly 20 positioned in the non-sterile field 110.
One skilled in the art will understand that even if the monitoring assembly 20 is positioned in the non-sterile field 110 near the user 30, the user 30 is not able to generally interact with items in the non-sterile field 110 and immediately return to the sterile field 104 to continue the operation on the subject 34. Therefore, positioning the remote 100 in the sterile field 104 allows the user 30 to use the remote 100 in the sterile field 104 to operate the monitoring assembly 20. The conductor 54 allows a signal from the remote control 100 to be carried to the monitoring assembly 20 and/or a stimulation signal from the monitoring system 20 to be delivered through the instrument 50 to the patient 34, such as to the nerve 36.
With continuing reference to
To assist in the rigid connection, the instrument 50 may include a connecting portion, such as a male connector 120 having an external wall 122 and an internal wall 124. The external wall 122 may have a non-circular geometry, such as a square shape. The square shape may assist in resisting or eliminating rotation of the controller 100 relative to the instrument 50. The remote 100, as specifically illustrated in
An electrical or conductive connection may be made via the connecting portions 120, 130 or other portions. For example, the instrument 50 may form a female conducting connection portion 140, such as with or on the internal wall 124. The internal wall 124 may include one or more conductors to connect with various portions of the instrument 50, such as providing multiple connections for a bi-polar or multi-polar stimulation. The remote 100 may include a male conductive connector 144 within the female connection 130. The male conductive connector 144 may be formed as a selected male connection, such as a banana plug or clip. The male connector 144 may make a conductive connection with the female connector 140 on the instrument 50. The male connector 144 may further be electrically connected to the conductor 54 that connects the remote 100 to the monitoring assembly 20. The conductor 54 allows for a physical connection of the remote 100 to the remote assembly 20. Therefore, the instrument 50 may be electrically and physically connected to the remote assembly 20 to allow for operation of the instrument 50 by the user 30 in the monitoring system 16.
The remote control 100 can include various control options including audio inputs, physical inputs, and the like. For example, the remote control 100 may include one or more push buttons such as a first push button 160, a second push button 164, and a third push button 168. Each of the push buttons 160, 164, and 168 may be physical buttons or members that move relative to the housing 136 to actuate a respective switch that is positioned below the button, but associated with the button on a printed circuit board (PCB) 172 positioned within the housing 136. The PCB 172 may include electrical switches 160a, 168a, 164a corresponding to the respective buttons 160, 168, and 164. The PCB 172 may include electrical connections or conductive connections from each of the switches 160a, 164a, and 168a to the conductor 54. Therefore, a signal from the respective switches 160a, 164a, and 168a may be transmitted to the monitoring assembly 20 to control and/or operate the monitoring assembly 20. It is understood that other appropriate switches may be provided such as mechanical toggle switches, touch sensitive portions (e.g., capacitive surfaces), a joystick, trackball, roller button (e.g. center rolling button on a computer mouse), or the like.
It is further understood that any appropriate number of input buttons or portions may be provided with the remote 100. Accordingly, including three buttons 160, 164, 168 are merely exemplary. Moreover, pressing or actuating more than one of the buttons at a time may operate the monitoring assembly 20 in a manner different and distinct from depressing any single one of the buttons 160, 164, 168 individually. Further, operating or depressing any one of the buttons in sequence in a selected amount of time (e.g., depressing a first button and a second button within two seconds of the first button) may operate the monitoring assembly 20 in a further different manner.
In various embodiments, the monitoring system 20 may be used to provide stimulation to the nerve 36 and receive a signal regarding an evoked response, such as in the muscle 70, such as through the contacts 40. Therefore, the user 30 may operate the remote control 100 to manually provide a stimulation pulse to the nerve 36, alter an amplitude of the stimulation pulse, alter a frequency of the stimulation pulse, or the like. According to various embodiments the remote control 100 may be operated to increase and/or decrease a stimulation current. For example, the first button 160 may be operated to increase stimulation current while the second button 164 may be operated to decrease the stimulation current. The buttons may include visual indicia to indicate a selected operation. For example, the first button 160 may be formed as an arrow or a triangle generally pointing “up” such as towards the instrument 50. The second button 164 may include a visual indication, such as an arrow or triangle pointing “down”, such as away, from the instrument 50, to assist in indicating a decrease in operation. The third button 168 may be a selection button, such as a menu selection, confirmation, or other general input that may be used to switch a current operation of the monitoring assembly 20.
The remote 100 may further be used to control the monitoring assembly 20 such as to increase or decrease an audio output or message from the monitoring assembly 20. Again, the first button 160 may be used to increase the volume while the second button 164 may be used to decrease the volume. The third button 168 may be used to cycle through various controllable options, such as between increasing and decreasing stimulation current and increasing and decreasing a message volume from the monitoring assembly 20.
The remote 100 may be further used to operate to collect information or store information being received or displayed by the monitoring assembly 20. Again, as discussed above, the electrodes 40 may receive an evoked response due to a stimulation of the nerve 36. The evoked response may be displayed on the display device 22 or otherwise presented as a message to the user 30. The remote 100 may be operated to acquire or save a snapshot (e.g., a screenshot) of information currently being displayed or represented by the monitoring assembly 20. For example, the display device 22 may display a graph regarding the perceived or sensed evoked response. Acquiring, a screenshot of the display device 22 allows the user 30 to save a selected signal received by the monitoring assembly 20 from the electrodes 40. The user 30 may use the saved screenshot, such as at a later time, for comparison to a later acquired or later received signal. Further, the saved screenshot may be used to assist in training at a later period.
The remote 100 may further be used to set or control threshold limits. Threshold limits may relate to stimulation current and/or voltage. Further, the threshold limits may relate to the received responses or received signals at the electrodes 40. The control threshold limit may set an upper or lower limit regarding a waveform that is identified as the received signal by the electrodes 40.
The remote control 100 may be further operated to operate a selected system. For example, the monitoring assembly 20 may be operated with a continuous or automatic pulse system. For example, the automatic periodic stimulation (APS® Stimulation System, sold by Medtronic, Inc.) may be connected with the nerve 36. The remote control 100 may be used to operate the periodic stimulation through an automatic periodic stimulation system. For example, adjusting a stimulation current may be made, similar to that discussed above, through the electrode. Further, the APS® Monitoring System may include various features such as determining a baseline evoked response from the periodic stimulation and alarm conditions relating to deviations from the baseline. The remote control 100 may be used to control the monitoring system 20 during and/or to initiate a baseline determination (e.g., inputting a beginning and ending time for identifying a baseline, changing the volume and/or muting a presented signal (e.g. a periodic tone relating to the evoked and sensed response), changing or controlling alarm conditions regarding a deviation from the baseline, and other appropriate features of the APS® Monitoring System). Accordingly, the remote control may be used to operate various features of the monitoring assembly 20 within the monitoring system 16.
Turning reference to
Nevertheless, it is understood that the remote 100 may be connected with selected instruments, such as either a single tip probe or a dual tip forceps, or other appropriate instrument. Moreover, it is understood that the remote 100 may be connected to a first instrument, disconnected from the first instrument 50, and then connected to the second instrument 200. The remote may then be disconnected from the second instrument 200 and reconnected to the first instrument 50. Further, it is understood that a kit of instruments may include any appropriate number of instruments and the remote 100 may be connected, disconnected, and reconnected to different instruments a selected number of times.
The remote 100 may be connected substantially directly to the instrument 50, 200 to allow for ease of operation of the remote by the user 30 while grasping the respective instrument 50, 200. The user 30 may use one or both hands 30a, 30b to manipulate both the instrument 50, 200 and/or the remote 100. The user 30 may use a digit of one or both hands to depress or operate the inputs, such as the buttons 160, 164, 168, to control the monitoring assembly 20. For example, only a single digit (e.g. finger of a hand) may be used to press the first button 160. As noted above, pressing the first button may increase a stimulation current.
According to various embodiments, however, as illustrated in
The connector 260 allows the remote 250 to be positioned a distance from the instrument 270. For example, the remote 250 may be connected to a holder, such as including a clip 280. The clip 280 may be clipped to a select portion, such as a sterile draping (e.g. placed over the subject 34 or portion near the subject 34) or to a garment of the user 30, to position the remote 250 near or at the user 30 and away from the patient 34. The user 30 may then move one or more of the hands 30a, 30b to operate the remote 250.
The remote 250 may be similar or identical to the remote 100 and includes the first button 160, the second button 164, and the third button 168. Further, the remote 250 may include any appropriate input portions including those discussed above. Nevertheless, the remote 250 may be positioned at a convenient and advantageous location for operation by the user 30. The instrument connector 260 may be connected via the conductor 54 to the monitoring assembly 20 in the non-sterile field 110. The instrument connector 260 may be interconnected with the conductor 54 and/or directly connected to the monitoring assembly 20. The instrument connection portion 260 may be provided to allow for positioning of the remote 250 at a selected location remote and away from the instrument 270. Therefore, it is understood that the remotes 250 may be positioned away from the instrument 270 for operation by the user 30. The remote 100, however, may be directly connected to the selected instrument to be operated by the user 30.
It is further understood, that the remote 250 may be positioned in line with the conductor 260. The remote 250 need not be connected to the instrument 200 or instrument 270, but need not be on a separated conductor connected to the conductor 260. Thus, the remote 250 may be positioned a distance from the instrument 270, but be electrically connected thereto, such as with the conductor 260.
Further, the clip 280 need not be rigidly connected to the remote 250. For example, the clip 280 may be connected to the conductor 260. The clip 280 may then be connected to an object, such as the surgeon 30, as discussed above, and the conductor 260 would then assist in maintaining the remote 250 near the surgeon 30. Thus, the clip 280 need not be formed as a part of the remote 250.
According to various embodiments, a display 300 may be included on the remote 100 or remote 250. For example, as illustrated in
The display 300 may display selected information to the surgeon 30, such as present operation of monitoring assembly 20. The present operation may include whether or not stimulation is occurring, the type of stimulation, stimulation current or voltage, etc. The display 300 may also display control options, such as START, STOP, CONTINUOUS, increase stimulation, decrease stimulation,
The screen 300 may also be used on the remote to operate the monitoring assembly 20, in a manner similar to that discussed above. For example, a selected type of operation may be displayed or selected by the surgeon 30. As illustrated in
The display 300 may display various icons and communications based on instructions that are stored and accessed by the processor 26. For example, the processor 26 may execute instructions to display on the display 300 a selection of a command to start and stop stimulation. The user may then operate the remote 100′, such as with the button 160, to select or highlight (e.g. with an underline displayed on the display 300) one of the displayed icons. The user 30 may then input a command by selecting, such as by depressing the button 168, the highlighted or selected icon. It is understood that such instructions may be incorporated into selected algorithms and instructions, as is understood by one skilled in the art.
According to various embodiments, the remote, such as the remote 100 need not be physically connected to the conductor 54 for communicating with the monitoring assembly 20. As discussed above, the conductor 54 allows a signal from the remote control 100 to be carried to the monitoring assembly 20 and/or a stimulation signal from the monitoring assembly 20 to be delivered through the instrument 50 to the patient 34, such as to the nerve 36. The remote 100, however, may include a wireless communication system or portion, such as those generally known in the art, to communicate with the monitoring assembly 20. The remote 100 may be operated, as discussed above, however, an instruction from the surgeon 30 may be communicated to the monitoring assembly 20 with a wireless or over the air (OTA) transmission. Also, transmissions from the monitoring assembly 20 regarding operation of the monitoring assembly 20 may be wireless or OTA to the remote 100. The conductor 54, or other selected conductor, may be connected to the selected instrument, such as the instrument 200, for providing the stimulation to the electrodes. Control, or at least selected control, of the monitoring assembly 20 may be with the remote 100 that is wirelessly communicating with the monitoring assembly 20.
Example embodiments are provided so that this disclosure will be thorough, and will fully convey the scope to those who are skilled in the art. Numerous specific details are set forth such as examples of specific components, devices, and methods, to provide a thorough understanding of embodiments of the present disclosure. It will be apparent to those skilled in the art that specific details need not be employed, that example embodiments may be embodied in many different forms and that neither should be construed to limit the scope of the disclosure. In some example embodiments, well-known processes, well-known device structures, and well-known technologies are not described in detail.
The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosure. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the disclosure, and all such modifications are intended to be included within the scope of the disclosure.
This application is a continuation of U.S. application Ser. No. 15/269,051 filed on Sep. 19, 2016. The entire disclosure of the above application is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4265237 | Schwanbom et al. | May 1981 | A |
4630263 | Townsend et al. | Dec 1986 | A |
5116332 | Lottick | May 1992 | A |
5767791 | Stoop et al. | Jun 1998 | A |
5921939 | Danielsson et al. | Jul 1999 | A |
6752816 | Culp et al. | Jun 2004 | B2 |
7216001 | Hacker et al. | May 2007 | B2 |
7236822 | Dobak, III | Jun 2007 | B2 |
7292886 | Kroll | Nov 2007 | B1 |
7496407 | Odderson | Feb 2009 | B2 |
7689292 | Hadzic et al. | Mar 2010 | B2 |
7789833 | Urbano et al. | Sep 2010 | B2 |
7987001 | Teichman et al. | Jul 2011 | B2 |
7993269 | Donofrio et al. | Aug 2011 | B2 |
8068910 | Gerber et al. | Nov 2011 | B2 |
8126736 | Anderson et al. | Feb 2012 | B2 |
8255045 | Gharib et al. | Aug 2012 | B2 |
8374673 | Adcox et al. | Feb 2013 | B2 |
8498717 | Lee et al. | Jul 2013 | B2 |
8515520 | Brunnett et al. | Aug 2013 | B2 |
8568312 | Cusimano Reaston et al. | Oct 2013 | B2 |
8568317 | Gharib et al. | Oct 2013 | B1 |
8594779 | Denison et al. | Nov 2013 | B2 |
8670830 | Carlson et al. | Mar 2014 | B2 |
8680986 | Costantino | Mar 2014 | B2 |
8688237 | Stanislaus et al. | Apr 2014 | B2 |
8805527 | Mumford et al. | Aug 2014 | B2 |
8886280 | Kartush | Nov 2014 | B2 |
8892259 | Bartol et al. | Nov 2014 | B2 |
8926509 | Magar et al. | Jan 2015 | B2 |
8956418 | Wasielewski et al. | Feb 2015 | B2 |
8989855 | Murphy et al. | Mar 2015 | B2 |
9031658 | Chiao et al. | May 2015 | B2 |
9078671 | Beale et al. | Jul 2015 | B2 |
9084550 | Bartol et al. | Jul 2015 | B1 |
9084551 | Brunnett et al. | Jul 2015 | B2 |
9204830 | Zand et al. | Dec 2015 | B2 |
9918669 | Brown et al. | Mar 2018 | B2 |
10039915 | McFarlin et al. | Aug 2018 | B2 |
10123731 | Brown et al. | Nov 2018 | B2 |
10368793 | Brown et al. | Aug 2019 | B2 |
10398369 | Brown et al. | Sep 2019 | B2 |
10849517 | Cantwell et al. | Dec 2020 | B2 |
10987506 | McFarlin et al. | Apr 2021 | B2 |
20020109621 | Khair et al. | Aug 2002 | A1 |
20020111624 | Witt et al. | Aug 2002 | A1 |
20030171747 | Kanehira et al. | Sep 2003 | A1 |
20030181798 | Ai-Ali | Sep 2003 | A1 |
20040135528 | Yasohara et al. | Jul 2004 | A1 |
20050075067 | Lawson et al. | Apr 2005 | A1 |
20050075578 | Gharib et al. | Apr 2005 | A1 |
20050085743 | Hacker et al. | Apr 2005 | A1 |
20050131464 | Heinrich et al. | Jun 2005 | A1 |
20050149143 | Libbus et al. | Jul 2005 | A1 |
20050159659 | Sawan et al. | Jul 2005 | A1 |
20050215993 | Phan | Sep 2005 | A1 |
20050267529 | Crockett et al. | Dec 2005 | A1 |
20060025702 | Sterrantino | Feb 2006 | A1 |
20060200219 | Thrope et al. | Sep 2006 | A1 |
20060241725 | Libbus et al. | Oct 2006 | A1 |
20060276702 | McGinnis | Dec 2006 | A1 |
20070083193 | Werneth | Apr 2007 | A1 |
20070191915 | Strother et al. | Aug 2007 | A1 |
20070260293 | Carpenter et al. | Nov 2007 | A1 |
20070270678 | Fadem et al. | Nov 2007 | A1 |
20070270918 | De Bel et al. | Nov 2007 | A1 |
20070282217 | McGinnis et al. | Dec 2007 | A1 |
20080051673 | Kong et al. | Feb 2008 | A1 |
20080077198 | Webb et al. | Mar 2008 | A1 |
20080183190 | Adcox et al. | Jul 2008 | A1 |
20080183915 | Iima | Jul 2008 | A1 |
20080214903 | Orbach | Sep 2008 | A1 |
20080218393 | Kuramochi et al. | Sep 2008 | A1 |
20080300650 | Gerber et al. | Dec 2008 | A1 |
20080306348 | Kuo et al. | Dec 2008 | A1 |
20090024187 | Erickson et al. | Jan 2009 | A1 |
20090054804 | Gharib et al. | Feb 2009 | A1 |
20090157141 | Chiao et al. | Jun 2009 | A1 |
20090177112 | Gharib et al. | Jul 2009 | A1 |
20090182322 | D'Amelio et al. | Jul 2009 | A1 |
20090182328 | D'Amelio et al. | Jul 2009 | A1 |
20090182330 | D'Amelio et al. | Jul 2009 | A1 |
20090182331 | D'Amelio et al. | Jul 2009 | A1 |
20090186577 | Ross et al. | Jul 2009 | A1 |
20090240117 | Chmiel et al. | Sep 2009 | A1 |
20090299439 | Mire et al. | Dec 2009 | A1 |
20100036280 | Ballegaard et al. | Feb 2010 | A1 |
20100130913 | Baynham et al. | May 2010 | A1 |
20100145178 | Kartush | Jun 2010 | A1 |
20100152811 | Flaherty | Jun 2010 | A1 |
20100152812 | Flaherty et al. | Jun 2010 | A1 |
20100160731 | Giovannini et al. | Jun 2010 | A1 |
20100168561 | Anderson | Jul 2010 | A1 |
20100191311 | Scheiner et al. | Jul 2010 | A1 |
20100280568 | Bulkes et al. | Nov 2010 | A1 |
20110004207 | Wallace et al. | Jan 2011 | A1 |
20110028860 | Chenaux et al. | Feb 2011 | A1 |
20110071418 | Stellar et al. | Mar 2011 | A1 |
20110160731 | Bleich et al. | Jun 2011 | A1 |
20110190596 | Hacker et al. | Aug 2011 | A1 |
20110230734 | Fain et al. | Sep 2011 | A1 |
20110230782 | Bartol et al. | Sep 2011 | A1 |
20110230783 | Bartol et al. | Sep 2011 | A1 |
20110237924 | McGusty et al. | Sep 2011 | A1 |
20110245647 | Stanislaus et al. | Oct 2011 | A1 |
20110270120 | McFarlin et al. | Nov 2011 | A1 |
20110270121 | Johnson et al. | Nov 2011 | A1 |
20120004516 | Eng et al. | Jan 2012 | A1 |
20120071784 | Melkent et al. | Mar 2012 | A1 |
20120245439 | Andre et al. | Sep 2012 | A1 |
20120330384 | Perryman et al. | Dec 2012 | A1 |
20130030257 | Nakata et al. | Jan 2013 | A1 |
20130090641 | McKinney et al. | Apr 2013 | A1 |
20130116678 | Koss et al. | May 2013 | A1 |
20130245722 | Ternes et al. | Sep 2013 | A1 |
20130253334 | Al-Ali et al. | Sep 2013 | A1 |
20130261422 | Gilmore et al. | Oct 2013 | A1 |
20130304059 | Allen, IV et al. | Nov 2013 | A1 |
20130345701 | Allen, IV et al. | Dec 2013 | A1 |
20140005753 | Carbunaru | Jan 2014 | A1 |
20140039491 | Bakos et al. | Feb 2014 | A1 |
20140058284 | Bartol et al. | Feb 2014 | A1 |
20140067007 | Drees et al. | Mar 2014 | A1 |
20140073985 | Sakai et al. | Mar 2014 | A1 |
20140074084 | Engeberg et al. | Mar 2014 | A1 |
20140275849 | Acquista | Sep 2014 | A1 |
20140275914 | Li et al. | Sep 2014 | A1 |
20140277259 | Rosenberg et al. | Sep 2014 | A1 |
20140303452 | Ghaffari | Oct 2014 | A1 |
20140316229 | Tognetti et al. | Oct 2014 | A1 |
20140336635 | Hart et al. | Nov 2014 | A1 |
20140364920 | Doan et al. | Dec 2014 | A1 |
20150012066 | Underwood | Jan 2015 | A1 |
20150088029 | Wybo | Mar 2015 | A1 |
20150112325 | Whitman | Apr 2015 | A1 |
20150157237 | Murphy et al. | Jun 2015 | A1 |
20150173636 | Mokelke et al. | Jun 2015 | A1 |
20150202395 | Fromentin | Jul 2015 | A1 |
20150230749 | Gharib | Aug 2015 | A1 |
20150238260 | Nau, Jr. | Aug 2015 | A1 |
20150250423 | Hacker et al. | Sep 2015 | A1 |
20160015299 | Chan et al. | Jan 2016 | A1 |
20160038072 | Brown et al. | Feb 2016 | A1 |
20160038073 | Brown et al. | Feb 2016 | A1 |
20160038074 | Brown et al. | Feb 2016 | A1 |
20160038225 | Couture et al. | Feb 2016 | A1 |
20160199659 | Jiang et al. | Jul 2016 | A1 |
20160206362 | Mehta et al. | Jul 2016 | A1 |
20160235999 | Nuta et al. | Aug 2016 | A1 |
20160262699 | Goldstone et al. | Sep 2016 | A1 |
20160270679 | Mahon et al. | Sep 2016 | A1 |
20160287112 | McFarlin et al. | Oct 2016 | A1 |
20160287861 | McFarlin et al. | Oct 2016 | A1 |
20160317053 | Srivastava | Nov 2016 | A1 |
20170202570 | Shelton, IV et al. | Jul 2017 | A1 |
20170202598 | Shelton, IV et al. | Jul 2017 | A1 |
20180078161 | Cantwell et al. | Mar 2018 | A1 |
20190021643 | Brown et al. | Jan 2019 | A1 |
20190021644 | Brown et al. | Jan 2019 | A1 |
Number | Date | Country |
---|---|---|
2016244152 | Nov 2017 | AU |
2957385 | Feb 2016 | CA |
2610843 | Apr 2004 | CN |
101528303 | Sep 2009 | CN |
101594830 | Dec 2009 | CN |
101594906 | Dec 2009 | CN |
102046098 | May 2011 | CN |
102238904 | Nov 2011 | CN |
102762251 | Oct 2012 | CN |
103608069 | Feb 2014 | CN |
104203129 | Dec 2014 | CN |
105744887 | Jul 2016 | CN |
1587418 | Oct 2005 | EP |
2452158 | Feb 2009 | GB |
2004500217 | Jan 2004 | JP |
2004503266 | Feb 2004 | JP |
2008508049 | Mar 2008 | JP |
2008519609 | Jun 2008 | JP |
2008538996 | Nov 2008 | JP |
2009268016 | Nov 2009 | JP |
2010515487 | May 2010 | JP |
2011224085 | Nov 2011 | JP |
2012516205 | Jul 2012 | JP |
2013503015 | Jan 2013 | JP |
2013506507 | Feb 2013 | JP |
2013505080 | Feb 2013 | JP |
2013525002 | Jun 2013 | JP |
2014117328 | Jun 2014 | JP |
2014524279 | Sep 2014 | JP |
2015513988 | May 2015 | JP |
2018514258 | Jun 2018 | JP |
20130052534 | May 2013 | KR |
1020130052534 | May 2013 | KR |
I331027 | Oct 2010 | TW |
9525472 | Sep 1995 | WO |
9937359 | Jul 1999 | WO |
0178831 | Oct 2001 | WO |
02082982 | Oct 2002 | WO |
03026482 | Apr 2003 | WO |
2004064632 | Aug 2004 | WO |
2006026482 | Mar 2006 | WO |
2008012398 | Jan 2008 | WO |
2010090835 | Aug 2010 | WO |
2011035311 | Mar 2011 | WO |
2011041684 | Apr 2011 | WO |
2011136962 | Nov 2011 | WO |
2011150502 | Dec 2011 | WO |
2012129574 | Sep 2012 | WO |
2013019757 | Feb 2013 | WO |
2013151770 | Oct 2013 | WO |
2015-069962 | May 2015 | WO |
2015123100 | Aug 2015 | WO |
2016160477 | Oct 2016 | WO |
Entry |
---|
Japanese Office Action regarding Japanese Patent Application No. 2020-135550, dated Dec. 28, 2021. |
Chinese Office Action regarding Patent Application No. 201780071018.2, dated Mar. 24, 2022. |
Japanese Office Action regarding Patent Application No. 2019-515506, dated Apr. 22, 2022. |
Japanese Office Action regarding Japanese Patent Application No. 2019515506, dated Feb. 4, 2022. |
Canadian Office Action regarding Canadian Application No. 3099052, dated Feb. 18, 2022. |
China-Decision on Rejection, corresponding to Chinese Application No. 201780071018.2, dated Sep. 23, 2022. |
Canadian Examination Report regarding Application No. 2,981,636, dated Mar. 9, 2022. |
Japanese Office Action regarding Application No. 2020-134805, dated May 11, 2022. |
Korean Office Action regarding Application No. 1020197010841, dated Feb. 3, 2022. |
Office Action dated Nov. 10, 2020 in corresponding/related Japanese Application No. Japanese Patent Appln. No. 2017-552026. |
Australian Examination Report dated Dec. 8, 2018 in corresponding/related Australian Application No. 2016244152. |
Australian Office Action dated Feb. 8, 2018 in corresponding/related Australian Application No. 2015301110. |
Canadian Office Action dated Dec. 11, 2017 in corresponding/related Canadian Application No. 2,957,385. |
Canadian Office Action dated Jul. 27, 2018 in corresponding/related Canadian Application No. 2,981,635. |
Cypress Perform. SPI-based CyFi™ Transceiver Data Sheet. Cypress Semiconductor Corporation. (Jun. 25, 2009) pp. 1-45. |
Examination Report dated Feb. 28, 2020 in corresponding/related Australian Application No. 2019201702. |
Examination Report dated Sep. 8, 2020, in corresponding/related Australian Application No. 2019203347. |
Examination Report dated Sep. 8, 2020, in corresponding/related Australian Application No. 2019203348. |
Extended European Search Report dated Jul. 1, 2020 in corresponding/related European Application No. 20176316.6. |
Hurley “Physiotherapy for Sleep Disturbance in Chronic Low Pack Pain: a Feasibility Randomised Controlled Trial” BMC Musculoskeletal Disorders; 11 pages; 2010. |
International Preliminary Report on Patentability dated Mar. 28, 2019 in corresponding/related International Application No. PCT/US2017/051825. |
International Preliminary Report on Patentability dated Oct. 12, 2017 in corresponding International Application No. PCT/US2016/023903. |
International Preliminary Report on Patentability dated Oct. 12, 2017 in corresponding/related International Application No. PCT/US2016/023910. |
International Search Report and Written Opinion for PCT/US2015/043844 dated Jan. 12, 2016. |
International Search Report and Written Opinion for PCT/US2016/023903 dated Sep. 19, 2016 which claims benefit of U.S. Appl. No. 14/678,485, filed Apr. 3, 2015. |
International Search Report and Written Opinion for PCT/US2016/023910 dated Aug. 5, 2016 which claims benefit of U.S. Appl. No. 14/578,452, filed Apr. 3, 2015. |
International Search Report and Written Opinion dated Nov. 29, 2017 in corresponding International Application No. PCT/US2017/051825. |
Invitation to Pay Additional Fees dated Jun. 10, 2016 for International Application No. PCT/US2016/023903 which corresponds to U.S. Appl. No. 14/678,485, filed Apr. 3, 2015. |
Japanese Office Action dated Mar. 22, 2018 in corresponding/related Australian Application No. 2017-506854. |
Japanese Office Action dated Nov. 26, 2018 in corresponding/related Japanese Application No. 2017-506854. |
Korean Office Action dated Aug. 21, 2018 in corresponding/related Korean Application No. 10-2017-7006340. |
Medtronic Xomed Inc. “APS Electrode Stimulator” Brochure, 10 pages, 2010. |
Office Action dated Apr. 14, 2020 in corresponding/related Chinese Application No. 201680030207.0. |
Office Action dated Apr. 2, 2020 in corresponding/related Chinese Application No. 201680030281.2. |
Office Action dated Apr. 22, 2019 in corresponding/related Chinese Application No. 201580053580.3. |
Office Action dated Aug. 18, 2020 in corresponding/related Brazilian Application No. BR112017002470-5. |
Office Action dated Aug. 26, 2020 in corresponding/related Korean Application No. 10-2019-7012435. |
Office Action dated Aug. 26, 2020 in corresponding/related Korean Application No. 10-2020-7007858. |
Office Action dated Feb. 13, 2019 in corresponding/related European Application No. 15753542.8. |
Office Action dated Feb. 20, 2019 in corresponding/related Korean Application No. 10-2017-7032059. |
Office Action dated Feb. 26, 2020 in corresponding/related Japanese Application No. 2019-050923. |
Office Action dated Feb. 5, 2020 in corresponding/related Indian Application No. 201717004436. |
Office Action dated Jun. 20, 2019 in corresponding/related Canadian Application No. 2,981,635. |
Office Action dated Jun. 30, 2020 in corresponding/related Chinese Application No. 201580053580.3. |
Office Action dated Nov. 3, 2020, in corresponding/related Canadian Application No. 2,957,385. |
Office Action dated Sep. 16, 2020 in corresponding/related Chinese Application No. 201680030207.0. |
Office Action regarding Australian Patent Application No. 2016243081, dated Dec. 21, 2019. |
Office Action regarding Canadian Patent Application No. 2957385, dated Dec. 12, 2019. |
Office Action regarding Chinese Patent Application No. 201580053580.3, dated Jan. 7, 2020 (with English Translation). |
Office Action regarding corresponding/related Japanese Patent Application No. 2017552026, dated Mar. 27, 2020. |
Office Action regarding European Patent Application No. 16712713.3, dated Dec. 6, 2019. |
Wustrack “Change in Physical Activity One Year after Lumbar Decompression with or without Fusion, is it Correlated to Self-Reported Outcome Scores?” Proceedings of NASS 20th Annual Meeting/the Spine Journal 5 (2005) IS-189S. |
Wustrack “Physical Activity does not correlate with HRQL Scores in Patients with Degeneratie Lumbar Conditions” Proceedings of the NASS 20th Annual Meeting/the Spine Journal 5 (2005) IS-189S. |
European Patent Office Brief Communication regarding Oral Proceedings, Date: Jan. 12, 2023, corresponding to European Application No. 20176316.3. |
European Office Action regarding Patent Application No. 20176316.6, dated Dec. 7, 2021. |
Rich Vogel, Understanding Anodal and Cathodal Stimulation, the ASNM Monitor, 2017, https://www.asnm.org/blogpost/1635804/290597/Understanding-Anodal-and-Cathodal-Stimulation. |
Office Action regarding Japanese Patent Application No. 2020-134805, dated Jul. 13, 2021 with English translation. |
Office Action regarding Japanese Patent Application No. 2020-135550, dated Jul. 5, 2021 with English translation. |
Office Action regarding European Patent Application No. 16715204.0, dated May 21, 2021. |
Chinese Office Action regarding Application No. 201780071018.2, dated Aug. 24, 2021. |
U.S. Appl. No. 15/269,051, filed Sep. 19, 2016, Cantwell, et al. |
U.S. Appl. No. 16/531,309, 2019-0357839, filed Aug. 5, 2019, Brown, et al. |
U.S. Appl. No. 16/142,224, 2019-0021643, filed Sep. 26, 2018, Brown, et al. |
U.S. Appl. No. 16/142,238, 2019-0021644, filed Sep. 26, 2018, Brown, et al. |
U.S. Appl. No. 16/552,708, 2019-0380639, filed Aug. 27, 2019, Brown, et al. |
U.S. Appl. No. 16/678,452, 2016-0287112, filed Apr. 3, 2015, Courtney, et al. |
U.S. Appl. No. 16/027,510, 2018-0345004, filed Jul. 5, 2018, Cantwell, et al. |
First Office Action—Request for the submission of an Opinion, corresponding to Korean Patent Application No. 10-2017-7032060 (corresponding to PCT/US2016/023910), dated Oct. 26, 2022. |
Office Action regarding Chinese Patent Application No. 201580053580.3, dated Mar. 1, 2021. |
Pre-Appeal Examination Report regarding Japanese Patent Application No. 2017-552026, dated Feb. 16, 2021. |
Office Action regarding Japanese Patent Application No. 2017-552026, dated Oct. 13, 2021 (with English Translation). |
Summons to Attend Oral Proceedings regarding European Patent Application No. 201763166, dated Sep. 26, 2022. |
European Patent Office—Office Action corresponding to EP 17 778 021.0, dated Nov. 22, 2022. |
Number | Date | Country | |
---|---|---|---|
20210000363 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15269051 | Sep 2016 | US |
Child | 17029472 | US |